|

Autologous CAR19 T lymphocytes Clinical Trials

1 actively recruiting trial

Pipeline

Phase 1: 1

Top Sponsors

  • Institute of Hematology and Blood Transfusion, Czech Republic1

Indications

  • Non-Hodgkin's Lymphoma Refractory1
  • Non-Hodgkin's Lymphoma, Relapsed1
  • Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia1
  • Cancer1

Other1 trial

CART19 Cells Effects in Patients with Relapsed or Refractory Acute Lymphoblastic Leukemia and Non-Hodgkin's Lymphoma
Phase 1

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.